KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Non Operating Income (2016 - 2026)

Emergent BioSolutions has reported Non Operating Income over the past 16 years, most recently at $2.9 million for Q1 2026.

  • For Q1 2026, Non Operating Income fell 95.84% year-over-year to $2.9 million; the TTM value through Mar 2026 reached -$42.0 million, down 683.33%, while the annual FY2025 figure was -$17.3 million, 49.42% up from the prior year.
  • Non Operating Income for Q1 2026 was $2.9 million at Emergent BioSolutions, up from -$22.8 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $69.7 million in Q1 2025 and troughed at -$66.3 million in Q2 2024.
  • A 5-year average of -$7.9 million and a median of -$3.7 million in 2025 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: crashed 3300.0% in 2022 and later skyrocketed 351.62% in 2025.
  • Year by year, Non Operating Income stood at -$30.6 million in 2022, then skyrocketed by 127.78% to $8.5 million in 2023, then plummeted by 312.94% to -$18.1 million in 2024, then fell by 25.97% to -$22.8 million in 2025, then soared by 112.72% to $2.9 million in 2026.
  • Business Quant data shows Non Operating Income for EBS at $2.9 million in Q1 2026, -$22.8 million in Q4 2025, and -$3.7 million in Q3 2025.